Development of potent and proteolytically stable human neuromedin U receptor agonists

An De Prins, Charlotte Martin, Yannick Van Wanseele, Louise Julie Skov, C. Tömböly, Dirk Tourwé, Vicky Caveliers, Ann Van Eeckhaut, Birgitte Holst, Mette Marie Rosenkilde, Ilse Smolders, Steven Ballet

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.

Original languageEnglish
Pages (from-to)887-897
Number of pages11
JournalEuropean Journal of Medicinal Chemistry
Volume144
DOIs
Publication statusPublished - Jan 20 2018

Fingerprint

neuromedin U 8
Plasma (human)
Half-Life
Physiological Phenomena
Peptides
Plasma stability
Molecules
Nociception
Feeding Behavior
Assays
Substitution reactions
Amino Acids
Degradation
neuromedin U
neuromedin U receptor

Keywords

  • Neuromedin U (NMU)
  • Neuromedin U receptor agonists
  • NMU-8
  • Plasma stability

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Development of potent and proteolytically stable human neuromedin U receptor agonists. / De Prins, An; Martin, Charlotte; Van Wanseele, Yannick; Skov, Louise Julie; Tömböly, C.; Tourwé, Dirk; Caveliers, Vicky; Van Eeckhaut, Ann; Holst, Birgitte; Rosenkilde, Mette Marie; Smolders, Ilse; Ballet, Steven.

In: European Journal of Medicinal Chemistry, Vol. 144, 20.01.2018, p. 887-897.

Research output: Contribution to journalArticle

De Prins, A, Martin, C, Van Wanseele, Y, Skov, LJ, Tömböly, C, Tourwé, D, Caveliers, V, Van Eeckhaut, A, Holst, B, Rosenkilde, MM, Smolders, I & Ballet, S 2018, 'Development of potent and proteolytically stable human neuromedin U receptor agonists', European Journal of Medicinal Chemistry, vol. 144, pp. 887-897. https://doi.org/10.1016/j.ejmech.2017.12.035
De Prins, An ; Martin, Charlotte ; Van Wanseele, Yannick ; Skov, Louise Julie ; Tömböly, C. ; Tourwé, Dirk ; Caveliers, Vicky ; Van Eeckhaut, Ann ; Holst, Birgitte ; Rosenkilde, Mette Marie ; Smolders, Ilse ; Ballet, Steven. / Development of potent and proteolytically stable human neuromedin U receptor agonists. In: European Journal of Medicinal Chemistry. 2018 ; Vol. 144. pp. 887-897.
@article{d8710a1e143a43e3ab4e58b51377b8f7,
title = "Development of potent and proteolytically stable human neuromedin U receptor agonists",
abstract = "Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.",
keywords = "Neuromedin U (NMU), Neuromedin U receptor agonists, NMU-8, Plasma stability",
author = "{De Prins}, An and Charlotte Martin and {Van Wanseele}, Yannick and Skov, {Louise Julie} and C. T{\"o}mb{\"o}ly and Dirk Tourw{\'e} and Vicky Caveliers and {Van Eeckhaut}, Ann and Birgitte Holst and Rosenkilde, {Mette Marie} and Ilse Smolders and Steven Ballet",
year = "2018",
month = "1",
day = "20",
doi = "10.1016/j.ejmech.2017.12.035",
language = "English",
volume = "144",
pages = "887--897",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Development of potent and proteolytically stable human neuromedin U receptor agonists

AU - De Prins, An

AU - Martin, Charlotte

AU - Van Wanseele, Yannick

AU - Skov, Louise Julie

AU - Tömböly, C.

AU - Tourwé, Dirk

AU - Caveliers, Vicky

AU - Van Eeckhaut, Ann

AU - Holst, Birgitte

AU - Rosenkilde, Mette Marie

AU - Smolders, Ilse

AU - Ballet, Steven

PY - 2018/1/20

Y1 - 2018/1/20

N2 - Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.

AB - Neuromedin U (NMU) is a highly conserved endogenous peptide that is involved in a wide range of physiological processes such as regulation of feeding behavior, the stress response and nociception. The major limitation to use NMU as a therapeutic is its short half-life. Here, we describe the development of a set of novel NMU-analogs based on NMU-8, by introducing unnatural amino acids into the native sequence. This approach shows that it is possible to generate molecules with increased potency and improved plasma stability without major changes of the peptidic nature or the introduction of large conjugates. When compared to the native NMU-8 peptide, compounds 16, 18 and 20 have potent agonist activity and affinity for both NMU receptors. Selectivity towards NMUR1 was observed when the Phe residue in position 4 was modified, whereas higher potencies at NMUR2 were found when substitutions of the Pro residue in position 6 were executed. To study the effect of the modifications on the proteolytic stability of the molecules, an in vitro stability assay in human plasma at 37 °C was performed. All analyzed analogs possessed an increased resistance against enzymatic degradation in human plasma resulting in half-lifes from 4 min for NMU-8, up to more than 23 h for compound 42.

KW - Neuromedin U (NMU)

KW - Neuromedin U receptor agonists

KW - NMU-8

KW - Plasma stability

UR - http://www.scopus.com/inward/record.url?scp=85040255285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040255285&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2017.12.035

DO - 10.1016/j.ejmech.2017.12.035

M3 - Article

C2 - 29329072

AN - SCOPUS:85040255285

VL - 144

SP - 887

EP - 897

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -